BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Antiverse

Antiverse logo

Founded
2017
Geography
United Kingdom based
Funding
$0.473 M

Antiverse is building a world-first computational antibody drug discovery platform to predict antibody-antigen binding and provide antibody drug candidates in one day.

A combination of state of the art machine learning and cell-free protein synthesis is used to predict antibodies that bind to a given antigen target with high affinity. The resulting software can then take antigen target sequence, provided by the customer, and do a high-throughput screening of all possibilities of antibody sequences to detect the sequence that will produce a high-affinity antibody for the target. The customer will be provided with the sequence in a single day, thus reducing the time typically required for antibody therapeutics discovery by 3 to 18 months.

Technologies

AI Companies (Drug Discovery)  

R&D Platform


Pipelines

No pipelines published yet

Products

 

Services

No services posted yet